Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Ryan Ziemiecki"'
Autor:
Matthew D. Rousculp, Kelly Hollis, Ryan Ziemiecki, Dawn Odom, Anthony M. Marchese, Mitra Montazeri, Shardul Odak, Laurin Jackson, Hadi Beyhaghi, Seth Toback
Publikováno v:
Vaccines, Vol 12, Iss 7, p 802 (2024)
Participants in studies investigating COVID-19 vaccines commonly report reactogenicity events, and concerns about side effects may lead to a reluctance to receive updated COVID-19 vaccinations. A real-world, post hoc analysis, observational 2019nCoV-
Externí odkaz:
https://doaj.org/article/4a6215e46a214139a474118ea9ab0af3
Autor:
Richard H. Osborne, Lauren M. Nelson, Sheri Fehnel, Nicole Williams, Randall H. Bender, Ryan Ziemiecki, Efi Gymnopoulou, Els De Paepe, Yannick Vandendijck, Lindsey Norcross, Esther Heijnen, Gabriela Ispas, Christy Comeaux, Benoit Callendret, Eric K. H. Chan, Jane A. Scott
Publikováno v:
Journal of Patient-Reported Outcomes, Vol 7, Iss 1, Pp 1-10 (2023)
Abstract Background The Respiratory Infection Intensity and Impact Questionnaire (RiiQ™) is a patient-reported outcome measure designed to assess symptoms and impacts of respiratory syncytial virus (RSV) infection. This study evaluated the construc
Externí odkaz:
https://doaj.org/article/5b724d2c15ed41cd898aa8d9498f4137
Autor:
Matthew D. Rousculp, Kelly Hollis, Ryan Ziemiecki, Dawn Odom, Anthony M. Marchese, Mitra Montazeri, Shardul Odak, Laurin Jackson, Angela Miller, Seth Toback
Publikováno v:
Vaccines, Vol 12, Iss 1, p 83 (2024)
As SARS-CoV-2 variants continue to emerge, vaccination remains a critical tool to reduce the COVID-19 burden. Vaccine reactogenicity and the impact on work productivity/daily activities are recognized as contributing factors to vaccine hesitancy. To
Externí odkaz:
https://doaj.org/article/a733523b797943a093085e517ba4b0e2
Autor:
Catherine B. Johannes, Daniel C. Beachler, J. Bradley Layton, Heather E. Danysh, Ryan Ziemiecki, Alejandro Arana, Jade Dinh, Ling Li, Brian Calingaert, Manel Pladevall-Vila, Phillip R. Hunt, Hungta Chen, Cecilia Karlsson, Kristina Johnsson, Alicia Gilsenan
Publikováno v:
Drug Safety. 46:157-174
Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor approved to treat type 2 diabetes mellitus (T2DM), among other conditions. When dapagliflozin was approved in Europe for treating T2DM (2012), potential safety concerns regarding its effect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9ebfbe422918481ffd13833f3c8960a
https://doi.org/10.1007/s40264-022-01263-3
https://doi.org/10.1007/s40264-022-01263-3
Autor:
Heather E. Danysh, Catherine B. Johannes, Daniel C. Beachler, J. Bradley Layton, Ryan Ziemiecki, Alejandro Arana, Jade Dinh, Ling Li, Brian Calingaert, Manel Pladevall-Vila, Phillip R. Hunt, Hungta Chen, Cecilia Karlsson, Kristina Johnsson, Alicia Gilsenan
Publikováno v:
Drug safety.
At the time of dapagliflozin's approval in Europe (2012) to treat patients with type 2 diabetes mellitus, concerns regarding acute liver injury and severe complications of urinary tract infection (sUTI) led to two post-authorization safety (PAS) stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::012da253059c17eaa578952965e56089
https://pubmed.ncbi.nlm.nih.gov/36583828
https://pubmed.ncbi.nlm.nih.gov/36583828
Autor:
Estel Plana, Miguel Cainzos-Achirica, Ryan Ziemiecki, Thomas M. MacDonald, Ana Ruigómez, Luis A. García-Rodríguez, Joan Fortuny, Elizabeth Andrews, Alicia Gilsenan, Robert W. V. Flynn
Publikováno v:
Drug Safety
Introduction A multinational post-authorization safety study assessed cardiovascular safety in initiators of prucalopride for chronic constipation compared with a matched cohort of polyethylene glycol 3350 initiators. The primary safety outcome was m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fdd4f30e5a27f6df14f8bfbe1a06ead3
http://europepmc.org/articles/PMC8053159
http://europepmc.org/articles/PMC8053159
Autor:
Thomas M. MacDonald, Joan Fortuny, Miguel Cainzos-Achirica, Elizabeth Andrews, Love Linnér, Ryan Ziemiecki, Alicia Gilsenan, Ana Ruigómez, Bianca Kollhorst, Oscar F. Cantero, Estel Plana, Tania Schink, Luis A. García-Rodríguez, Pär Karlsson, Robert W. V. Flynn
Publikováno v:
Drug safety, 42(10):1167-1177
Drug Safety
Drug Safety
Introduction Given prior safety experience with other 5-HT4 agonists for chronic constipation, an observational, population-based cohort study in five data sources from Germany, Sweden, and the UK was conducted to evaluate the cardiovascular safety o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44535feb620192b003078fec54e34ddb
https://doi.org/10.1007/s40264-019-00836-z
https://doi.org/10.1007/s40264-019-00836-z
Autor:
Cecilia Karlsson, Alicia Gilsenan, Ryan Ziemiecki, Heather Elizabeth Danysh, Catherine Johannes, J. Bradley Layton, Ling Li, Jade Dinh, DC Beachler, Hungta Chen, PR Hunt
Publikováno v:
Diabetes. 70
A noninterventional postauthorization safety study in adult patients with type 2 diabetes compared the incidence of hospitalized diagnoses of acute kidney injury (hAKI) in new users of dapagliflozin and new users of comparator glucose-lowering drugs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0baa2e31df6f19c2c4de9a0d9f0e09e8
https://doi.org/10.2337/db21-14-or
https://doi.org/10.2337/db21-14-or
Autor:
PR Hunt, Catherine Johannes, J. Bradley Layton, Ling Li, DC Beachler, Hungta Chen, Heather Elizabeth Danysh, Jade Dinh, Ryan Ziemiecki, Alicia Gilsenan, Cecilia Karlsson
Publikováno v:
Diabetes. 70
A noninterventional postauthorization safety study of patients with type 2 diabetes compared the incidence of hospitalized acute liver injury (hALI) in new users of dapagliflozin and new users of comparator glucose-lowering drugs (GLDs), matched on y
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7d42a9bb707e469d14ef8ddebe061695
https://doi.org/10.2337/db21-806-p
https://doi.org/10.2337/db21-806-p
Autor:
J. Bradley Layton, Ling Li, DC Beachler, Hungta Chen, Catherine Johannes, Alicia Gilsenan, Cecilia Karlsson, Heather Elizabeth Danysh, Ryan Ziemiecki, Jade Dinh, PR Hunt
Publikováno v:
Diabetes. 70
A noninterventional postauthorization safety study in patients with type 2 diabetes compared the sex-specific incidence of severe complications of urinary tract infections (sUTI) (pyelonephritis or urosepsis) in new users of dapagliflozin and new use
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::82cb376cf2dc99658c6c3c60976b13f4
https://doi.org/10.2337/db21-805-p
https://doi.org/10.2337/db21-805-p